Home » Stocks » PRAH

PRA Health Sciences, Inc. (PRAH)

Stock Price: $97.44 USD -1.28 (-1.30%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 6.23B
Revenue (ttm) 3.09B
Net Income (ttm) 212.34M
Shares Out 63.96M
EPS (ttm) 3.27
PE Ratio 29.80
Forward PE 17.67
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $97.44
Previous Close $98.72
Change ($) -1.28
Change (%) -1.30%
Day's Open 98.54
Day's Range 95.84 - 99.47
Day's Volume 259,458
52-Week Range 58.67 - 113.41

More Stats

Market Cap 6.23B
Enterprise Value 7.56B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 63.96M
Float 63.81M
EPS (basic) 3.34
EPS (diluted) 3.27
FCF / Share 4.32
Dividend n/a
Dividend Yield n/a
Earnings Yield 3.36%
FCF Yield 4.37%
Payout Ratio n/a
Shares Short 1.42M
Short Ratio 4.02
Short % of Float 2.22%
Beta 1.05
PE Ratio 29.80
Forward PE 17.67
P/FCF Ratio 22.87
PS Ratio 2.01
PB Ratio 5.48
Revenue 3.09B
Operating Income 304.25M
Net Income 212.34M
Free Cash Flow 272.57M
Net Cash -1.32B
Net Cash / Share -20.69
Gross Margin 49.34%
Operating Margin 9.83%
Profit Margin 6.90%
FCF Margin 8.81%
ROA 5.36%
ROE 18.22%
ROIC 17.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (15)

Buy 4
Overweight 1
Hold 8
Underweight 2
Sell 0

Analyst Consensus: Overweight

Price Target

$113.77*
(16.76% upside)
Low
100
Current: $97.44
High
130
Target: 113.77
*Average 12-month price target from 13 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue3,0662,8722,2591,8121,6141,460
Revenue Growth6.77%27.11%24.71%12.26%10.57%-
Gross Profit877801665547489407
Operating Income36428117616316354.59
Net Income24315486.9368.1881.77-35.74
Shares Outstanding64.5164.1262.4460.7659.9742.90
Earnings Per Share3.682.321.321.061.29-0.83
EPS Growth58.62%75.76%24.53%-17.83%--
Operating Cash Flow25433022016015234.03
Capital Expenditures-74.27-55.84-61.26-33.13-32.77-27.32
Free Cash Flow1792741591271206.71
Cash & Equivalents23614519314912691.53
Total Debt1,4641,0821,346828890924
Net Cash / Debt-1,228-938-1,153-679-763-833
Assets3,5443,1863,3582,1902,2292,214
Liabilities2,4542,1352,4221,4611,5261,538
Book Value1,0901,045931729703677
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name PRA Health Sciences, Inc.
Country United States
Employees 17,500
CEO Colin Shannon

Stock Information

Ticker Symbol PRAH
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: PRAH
IPO Date November 13, 2014

Description

PRA Health Sciences, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company has a partnership with The Leukemia & Lymphoma Society to launch a clinical trial for developing treatments for children with relapsed acute leukemia. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.